DPP-4 Inhibitor Sitagliptin Improves Cardiac Function and Glucose Homeostasis and Ameliorates <i>β</i>-Cell Dysfunction Together with Reducing S6K1 Activation and IRS-1 and IRS-2 Degradation in Obesity Female Mice

<div>(a) and (b) illustrate the normal appearance of the myocardial structure in the CD group and CD + SIT group. The myocardial structure in WD mice showed a severe myocardial structure injury, including a loose arrangement of myocardial cell, irregular part of the myocardial fiber fracture, apparent vacuole degeneration, myocardial interstitial hyperemia and edema, and a small amount of inflammatory cell infiltration mainly composed of lymphocytes (c). SIT treatment improved the myocardial arrangement, swollen cells, hyperemic edema, and lymphocyte infiltration (d).</div>

Journal of Diabetes Research

fig3

Figure 3

Figure 3: DPP-4 Inhibitor Sitagliptin Improves Cardiac Function and Glucose Homeostasis and Ameliorates <i>β</i>-Cell Dysfunction Together with Reducing S6K1 Activation and IRS-1 and IRS-2 Degradation in Obesity Female Mice 

Figure 3 | DPP-4 Inhibitor Sitagliptin Improves Cardiac Function and Glucose Homeostasis and Ameliorates β-Cell Dysfunction Together with Reducing S6K1 Activation and IRS-1 and IRS-2 Degradation in Obesity Female Mice 